Cargando…

Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study

INTRODUCTION: Interstitial lung disease (ILD) is a common extra-articular condition in rheumatoid arthritis (RA), but few studies have systematically investigated its incidence and risk factors in patients receiving anti-tumor necrosis factor-alpha (anti-TNFα) agents or alternate mechanisms of actio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curtis, Jeffrey R., Sarsour, Khaled, Napalkov, Pavel, Costa, Laurie A., Schulman, Kathy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641344/ https://www.ncbi.nlm.nih.gov/pubmed/26555431 http://dx.doi.org/10.1186/s13075-015-0835-7

Ejemplares similares

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
por: Crnkic Kapetanovic, Meliha, et al.
Publicado: (2013)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies
por: Rodina, Yulia, et al.
Publicado: (2021)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources
por: Monemi, Sharareh, et al.
Publicado: (2016)

Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience
por: Maccora, Ilaria, et al.
Publicado: (2022)

EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden
por: Gülfe, Anders, et al.
Publicado: (2016)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
por: Takahashi, Nobunori, et al.
Publicado: (2013)

Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study
por: Blumentals, William A, et al.
Publicado: (2012)

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study
por: Bouman, Chantal A M, et al.
Publicado: (2018)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
por: Talmon, Maria, et al.
Publicado: (2023)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
por: Hirabara, Shinya, et al.
Publicado: (2014)

The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis
por: Tada, Yoshifumi, et al.
Publicado: (2016)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring during Abatacept and Adalimumab Therapy for Rheumatoid Arthritis
por: Yoshimura, Yusuke, et al.
Publicado: (2022)

Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
por: Tardella, Marika, et al.
Publicado: (2021)

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
por: Tardella, Marika, et al.
Publicado: (2022)

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors
por: Han, Xue, et al.
Publicado: (2021)

Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis
por: Napalkov, Pavel, et al.
Publicado: (2013)

Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card
por: Sarsour, Khaled, et al.
Publicado: (2020)

Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
por: Cassone, Giulia, et al.
Publicado: (2020)

Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Mena-Vázquez, Natalia, et al.
Publicado: (2022)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
por: Chiu, Yee, et al.
Publicado: (2012)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
por: Tymms, Kathleen, et al.
Publicado: (2021)

Interstitial lung disease in patients with scleroderma - Treatment with rituximab
por: Muñoz, A, et al.
Publicado: (2010)

Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
por: Lee, Yuna, et al.
Publicado: (2006)

Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis
por: Sainz-Prestel, Valeria, et al.
Publicado: (2013)

Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
por: Bai, Xueyan, et al.
Publicado: (2015)

The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
por: Navarro Coy, Nuria C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bj02uj9d87kodopocv0318oatm